Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Cefiderocol Activity vs. Resistant Enterobacterales: Insight

    2026-06-07

    Benchmarking Cefiderocol Against Resistant Enterobacterales: Relevance for CNS Infection Modeling

    Study Background and Research Question

    Carbapenem-resistant Enterobacterales (CRE) pose an urgent public health challenge, distinguished by high rates of multidrug resistance and limited therapeutic options. These Gram-negative bacteria, prevalent in severe hospital-acquired infections—including central nervous system (CNS) infections—are classified by the World Health Organization as critical priority pathogens. In light of the increasing reports of resistance to both carbapenems and β-lactam/β-lactamase inhibitor combinations throughout Europe, the reference study (Santerre Henriksen et al., 2024) sought to clarify the comparative in vitro efficacy of cefiderocol, a siderophore cephalosporin, against a comprehensive panel of clinical Enterobacterales isolates, including those resistant to meropenem and contemporary β-lactam/β-lactamase inhibitor regimens. This research context is directly relevant for scientists engaged in central nervous system infection research and antimicrobial resistance profiling.

    Key Innovation from the Reference Study

    The core innovation of the study lies in its large-scale, geographically diverse collection of 1,909 Enterobacterales isolates from 49 European clinical sites. By systematically testing these isolates—including 148 meropenem-resistant strains—against cefiderocol and a range of both approved and developmental β-lactam/β-lactamase inhibitor combinations, the authors provided the first head-to-head comparison of these agents' in vitro activity in a pan-European context. The explicit targeting of isolates with resistance to both meropenem and newer β-lactam/β-lactamase inhibitors offers critical insights for designing bacterial infection models that mirror real-world resistance challenges (reference study).

    Methods and Experimental Design Insights

    Isolates were subjected to standardized susceptibility testing using broth microdilution to determine minimum inhibitory concentrations (MICs) for cefiderocol, meropenem, and an array of β-lactam/β-lactamase inhibitor combinations, including ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, and cefepime-taniborbactam. Meropenem resistance was defined conservatively at an MIC >8 mg/L, corresponding to high-dose clinical breakpoints and ensuring clinical relevance in the resistance definition. PCR and whole-genome sequencing were employed to elucidate resistance mechanisms in both meropenem-resistant and cefiderocol-resistant isolates, particularly focusing on carbapenemase gene content and mutations in iron uptake pathways or cell wall synthesis genes.

    • Isolate diversity: Included Klebsiella spp. (970), Escherichia coli (382), and Enterobacter spp. (244), frequently from bloodstream infections (43.6%).
    • Resistance mechanism analysis: PCR-targeted carbapenemase genes (e.g., KPC, NDM, OXA variants); whole-genome sequencing for multidimensional resistance mapping.
    • Comparative groups: All Enterobacterales, meropenem-resistant only, β-lactam/β-lactamase inhibitor-resistant only, and dual-resistant isolates.

    Core Findings and Why They Matter

    The study found that cefiderocol demonstrated significantly higher susceptibility rates compared to all currently approved β-lactam/β-lactamase inhibitor combinations. Specifically, cefiderocol inhibited 98.1% of all Enterobacterales, outperforming the 78.1%–97.4% susceptibility rates observed for comparator regimens. For the 148 meropenem-resistant isolates—many of which harbored Klebsiella pneumoniae carbapenemase (KPC) genes—cefiderocol retained activity in 87.8% of cases, versus 0%–71.6% for approved combinations. Notably, in dual-resistant isolates (resistant to both meropenem and β-lactam/β-lactamase inhibitors), cefiderocol’s activity (61.9%–65.9%) was substantially greater than any approved alternative.

    Mechanistically, most cefiderocol-resistant isolates carried multiple resistance determinants, including iron uptake mutations and carbapenemase genes, underscoring the evolutionary complexity of multidrug resistance. These findings highlight the value of incorporating cefiderocol (and analogues) into bacterial infection model workflows that simulate contemporary resistance phenotypes. The high activity of cefiderocol against diverse, multidrug-resistant isolates—including those relevant to CNS infection—provides a robust evidence base for its prioritization in research applications (study details).

    Comparison with Existing Internal Articles

    While the reference study focuses on cefiderocol, parallels can be drawn for modeling workflows involving other blood-brain barrier-crossing cephalosporins such as Cefepime (BMY-28142). Internal reviews such as "Cefepime (BMY-28142): Applied Models for Antimicrobial Profiling" and "Cefepime (BMY-28142): Advanced Research Insights" emphasize Cefepime’s established antimicrobial activity against Gram-positive and Gram-negative bacteria, as well as its use in CNS infection models due to its blood-brain barrier penetration. These articles provide practical guidance for optimizing reproducibility and handling neurotoxicity during experimental design. In contrast, the reference study’s comprehensive resistance profiling and molecular epidemiological approach can inform researchers seeking to structure multidrug resistance panels or validate susceptibility testing protocols for cephalosporin antibiotics in CNS or systemic infection models.

    Notably, the workflows outlined in "Applied Workflows with Cefepime (BMY-28142) in Resistance Research" align with the reference study’s emphasis on assay reproducibility and multidrug resistance validation, reinforcing the necessity for standardized susceptibility testing and molecular diagnostics in experimental pipelines.

    Limitations and Transferability

    Although the reference study’s scale and diversity are strengths, its reliance on in vitro methods means that pharmacokinetic and host immune factors—key to CNS infection outcomes—are not addressed. Furthermore, while cefiderocol showed high activity even against extensively resistant isolates, resistance was not universal, with certain genotypes (e.g., NDM, AmpC, or OXA-type carbapenemases) associated with reduced susceptibility. Transferability to other cephalosporins such as cefepime should be approached with caution; although similar blood-brain barrier penetration and spectrum of activity exist, differences in resistance mechanisms and clinical breakpoints may affect experimental outcomes. Researchers modeling CNS or systemic infections must therefore consider both the molecular resistance profile and pharmacological characteristics of the chosen agent when designing comparative studies.

    Protocol Parameters

    • Isolate selection: Include both meropenem- and β-lactam/β-lactamase inhibitor-resistant Enterobacterales to mirror contemporary resistance challenges (study protocol).
    • Susceptibility testing: Broth microdilution is recommended for determining MICs of cephalosporins and comparators; ensure adherence to current CLSI/EUCAST standards.
    • Molecular profiling: Integrate PCR and/or whole-genome sequencing to confirm carbapenemase genes (e.g., KPC, NDM, OXA) and identify iron uptake pathway mutations.
    • CNS infection modeling: For blood-brain barrier-crossing antibiotics, confirm compound penetration and stability under simulated CNS conditions, as highlighted in internal workflows.
    • Neurotoxicity controls: When using cephalosporins such as Cefepime (BMY-28142), implement neurotoxicity monitoring and dose adjustment protocols, following established research guidance.

    Research Support Resources

    Researchers seeking to construct or validate antimicrobial activity assays against resistant Gram-negative pathogens can leverage the findings of the reference study to inform isolate selection, molecular diagnostics, and susceptibility testing protocols. For experimental modeling of CNS and systemic infections, Cefepime (BMY-28142) (SKU BA1013) is available as a research-grade, broad-spectrum cephalosporin with proven blood-brain barrier penetration and antimicrobial activity against key Gram-positive and Gram-negative bacteria. APExBIO’s formulation is supplied as a solid and should be stored at -20°C; prompt use after solution preparation is recommended to maintain assay fidelity. Researchers are advised to follow compound-specific neurotoxicity and dosing precautions as outlined in product documentation and detailed internal workflows. This resource can be integrated into resistance modeling and CNS infection research pipelines to complement the approaches validated in the reference study.